US Republic Times

Oil and Gas Automation Market 2021 Global Industry Growth, Demand, Size Analysis, Share, Revenue and Forecast 2026

absolutereports

“Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market” is the process of conveying a good quality service to customers. focuses on identifying hidden needs or requirements of customers. Report defines the scope of the Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market, identifying potential of the Sodium-dependent Glucose Co-transporter 2 (SGLT 2) markets and determining optimal pricing for the market, it encouraging potential customers to purchase, and finding the best distribution methods for delivering to customers.

Get a Sample Copy of the Report – https://www.absolutereports.com/enquiry/request-sample/13999739

Market Overview:

  • The SGLT2 inhibitors class of drugs include Jardiance, Fraxiga, Inovokana, and Suglat, among others. The demand for SGLT2 is expected to grow immensely, due to drugs like Jardiance and Farxiga.
  • The growing global type-2 diabetes population promotes the growth of SGLT2 drugs. The global SGLT2 market has a high potential for growth, due to the increasing number of diabetic patients and their need for drugs that help reduce high blood glucose levels, despite being on a medication regimen, such as metformin and insulin. SGLT2 serves this specific purpose.
  • The global market for SGLT2 is worth USD 6,573.8 million in 2019 and is expected to grow at CAGR of 16% by 2024.

    Key Market Trends: – Jardiance is Leading the SGLT2 Market.

    Jardiance, which was released globally in 2014, is a once-daily oral medication that is used to control blood glucose levels in people with type-2 diabetes.
    Jardince is gaining sales when compared to Invokana, with patients preferring this drug, as it has a lower risk of cardiovascular diseases when compared to other SGLT2 drugs, by helping the kidneys remove glucose from the bloodstream.
    Jardiance accounted for 41.5% of the sales in the global SGLT2 class of drugs in 2017. The market for Jardince was worth USD 2.5 billion in 2018 and is expected to grow at a CAGR of 15.78%, during the forecast period (2019-2024).

    65% of the Market Share is Occupied by North America.
    The growing global type-2 diabetes population promotes the growth of SGLT2 drugs. North America accounts for the highest type- 2 diabetic population. Prices are comparatively high in this region.
    The North America SGLT2 market accounts for USD 3,471.5 million in 2018 and is expected to grow at CAGR of 15.5% by 2024.
    In the United States, there are close to 900 lawsuits currently pending, regarding Invokana. Jardiance holds 50% of the market share in the US SGLT2 market.

    Inquire or Share Your Questions If Any Before the Purchasing This Report:-https://www.absolutereports.com/enquiry/pre-order-enquiry/13999739  

    Major Key Players are as Follows

  • Eli Lilly
  • Janssen Pharmaceuticals
  • Astellas
  • Boehringer Ingelheim
  • AstraZeneca
  • Bristol Myers Squibb

    Scope of the Report:

  • The report includes a complete study of SGLT2 inhibitors, which include Invokana, Jardiance, Farxiga, and Suglat. The study is further divided into regional- and country-wise analyses, which cover all the drugs in the SGLT2 class.

    Geographical Regions:

    – United States – Canada – France – Germany – Italy – Spain – United Kingdom – Russia – Mexico – Brazil – Japan – South Korea – China – – Australia – Vietnam – Malaysia – Indonesia – Philippines – Thailand – Saudi Arabia – Iran – Egypt – Oman – South Africa.

    Topics such as sales and sales revenue overview, production market share by product type, capacity and production overview, import, export, and consumption are covered under the development trend section of the Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market report.

    Get a Sample Copy of the Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Report 2021

    Reasons to Purchase Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Report Covered:

    • The report examines how Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market will develop in the future.
    • Studying various views of the Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market with the help of Porter’s five forces analysis.
    • Analyzing the product type that is probable to control the market and regions that are likely to witness the fastest development during the forecast period
    • Identify the new developments, Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market shares and strategies employed by the key market players.
    • Competitive landscape including the market share of major players along with the key strategies accepted for growth in the past five years
    • Complete company profiles covering the product offerings, key financial information, current developments, SWOT analysis and strategies employed by the major Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market players

    Detailed TOC of Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market – Growth, Trends, and Forecast (2019 – 2024)

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Drug
    5.1.1 Sodium – Glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
    5.1.1.1 Invokana (Canagliflozin)
    5.1.1.2 Jardiance (Empagliflozin)
    5.1.1.3 Farxiga/Forxiga (Dapagliflozin)
    5.1.1.4 Suglat (Ipragliflozin)
    5.2 Geography
    5.2.1 North America
    5.2.1.1 United States (Value and Volume 2012-2024)
    5.2.1.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.1.2 Canada (Value and Volume 2012-2024)
    5.2.1.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.1.3 Rest of North America (Value and Volume 2012-2024)
    5.2.1.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2
    5.2.2.1 France (Value and Volume 2012-2024)
    5.2.2.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2.2 Germany (Value and Volume 2012-2024)
    5.2.2.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2.3 Italy (Value and Volume 2012-2024)
    5.2.2.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2.4 Spain (Value and Volume 2012-2024)
    5.2.2.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2.5 UK (Value and Volume 2012-2024)
    5.2.2.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2.6 Russia (Value and Volume 2012-2024)
    5.2.2.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.2.7 Rest of (Value and Volume 2012-2024)
    5.2.2.7.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.3 Latin America
    5.2.3.1 Mexico (Value and Volume 2012-2024)
    5.2.3.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.3.2 Brazil (Value and Volume 2012-2024)
    5.2.3.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.3.3 Rest of Latin America (Value and Volume 2012-2024)
    5.2.3.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4 Asia-Pacific
    5.2.4.1 Japan (Value and Volume 2012-2024)
    5.2.4.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.2 South Korea (Value and Volume 2012-2024)
    5.2.4.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.3 China (Value and Volume 2012-2024)
    5.2.4.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.4 (Value and Volume 2012-2024)
    5.2.4.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.5 Australia (Value and Volume 2012-2024)
    5.2.4.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.6 Vietnam (Value and Volume 2012-2024)
    5.2.4.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.7 Malaysia (Value and Volume 2012-2024)
    5.2.4.7.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.8 Indonesia (Value and Volume 2012-2024)
    5.2.4.8.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.9 Philippines (Value and Volume 2012-2024)
    5.2.4.9.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.10 Thailand (Value and Volume 2012-2024)
    5.2.4.10.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.4.11 Rest of Asia-Pacific (Value and Volume 2012-2024)
    5.2.4.11.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.5 Middle East & Africa
    5.2.5.1 Saudi Arabia (Value and Volume 2012-2024)
    5.2.5.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.5.2 Iran (Value and Volume 2012-2024)
    5.2.5.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.5.3 Egypt (Value and Volume 2012-2024)
    5.2.5.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.5.4 Oman (Value and Volume 2012-2024)
    5.2.5.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.5.5 South Africa (Value and Volume 2012-2024)
    5.2.5.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
    5.2.5.6 Rest of Middle & Africa (Value and Volume 2012-2024)
    5.2.5.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

    6 MARKET INDICATORS
    6.1 Type-1 Diabetes Population (2012-2024)
    6.2 Type-2 Diabetes Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 COMPANY PROFILES
    7.1.1 Eli Lilly
    7.1.2 Janssen Pharmaceuticals
    7.1.3 Astellas
    7.1.4 Boehringer Ingelheim
    7.1.5 AstraZeneca
    7.1.6 Bristol Myers Squibb
    7.2 MARKET SHARE ANALYSIS
    7.2.1 Eli Lilly
    7.2.2 Janssen Pharmaceuticals
    7.2.3 Astellas
    7.2.4 Boehringer Ingelheim
    7.2.5 AstraZeneca

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

    Purchase this Report (Price 5000 USD for a Single-User License) at https://www.absolutereports.com/purchase/13999739 

     

    Contact Info:

    Name: Ajay More

    Email: sales@absolutereports.com 

    Organization: Absolute Reports

    • Exit mobile version